On March 3, 2022 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental health medicines, reported that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in three upcoming investor conferences (Press release, Enveric Biosciences, MAR 3, 2022, View Source [SID1234609478]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Q1 Virtual Investor Summit
Tuesday, March 8th at 11:45 a.m. ET
To attend, please register here.
Citi’s Psychedelic Drug Call Series
Thursday, March 10th at 10:00 a.m. ET
A fireside chat hosted by Neena Bitritto-Garg, Citi’s Biotech analyst.
Maxim 2022 Virtual Growth Conference
Monday, March 28th – Wednesday, March 30th
To attend, please register here.
For more information about the events, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate Investor Summit Group, Citi, or Maxim representative, respectively, or send an email to KCSA Strategic Communications at [email protected].